Do you want to read an article? Please log in or register.
Chimeric antigen receptor T-cell therapy for acute lymphocytic leukaemia: where are we in 2020?
Leukemia
Related content
RECOMMENDED
Leukemia
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis
★ 2
Recommended by
Alexander Meisel, Faculty Member
Lancet Haematol.
Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS
doi: 10.1016/S2352-3026(20)30277-5.
Leukemia
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
J Clin Oncol.
Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG
doi: 10.1200/JCO.2017.72.8519.
Leukemia
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia
J Clin Oncol.
Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, Svoboda J, Stadtmauer E, Landsburg DJ, Mato A, Levine BL, Lacey SF, Melenhorst JJ, Veloso E, Gaymon A, Pequignot E, Shan X, Hwang WT, June CH, Porter DL
doi: 10.1200/JCO.19.03237.
Leukemia
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
J Clin Oncol.
Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, Dulau-Florea A, Salem D, Wang HW, Yuan C, Stetler-Stevenson M, Panch S, Tran M, Mackall CL, Stroncek DF, Fry TJ
doi: 10.1200/JCO.19.03279.
Lung, Respiratory and Thoracic CancerLeukemiaLymphoma
Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies
J Thorac Oncol.
Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS
doi: 10.1016/j.jtho.2017.10.001.
Leukemia
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
J Clin Oncol.
Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL
doi: 10.1200/JCO.19.01892.
Lymphoma
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
N Engl J Med.
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH
doi: 10.1056/NEJMoa1708566.
Leukemia
Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric Antigen Receptor T Cell Therapy
Blood
Wudhikarn K, Flynn JR, Rivière I, Gonen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, Halton EF, Diamonte C, Davila ML, Sadelain M, Brentjens RJ, Park J
doi: 10.1182/blood.2020009515
Non-Malignant Blood DisordersLymphomaMultiple Myeloma (MM)
Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
Lancet Haematol
Azoulay É, Castro P, Maamar A, Metaxa V, de Moraes AG, Voigt L, Wallet F, Klouche K, Picard M, Moreau AS, Van De Louw A, Seguin A, Mokart D, Chawla S, Leroy J, Böll B, Issa N, Levy B, Hemelaar P, Fernandez S, Munshi L, Bauer P, Schellongowski P, Joannidis M, Moreno-Gonzalez G, Galstian G, Darmon M, Valade S, Nine-I investigators.
doi: 10.1016/S2352-3026(21)00060-0